| Literature DB >> 21517933 |
T T Sjursen1, G B Lygre, K Dalen, V Helland, T Laegreid, J Svahn, B F Lundekvam, L Björkman.
Abstract
The aim of the present study was to investigate whether removal of all amalgam fillings was associated with long-term changes in health complaints in a group of patients who attributed subjective health complaints to amalgam fillings. Patients previously examined at the Norwegian Dental Biomaterials Adverse Reaction Unit were included in the study and assigned to a treatment group (n = 20) and a reference group (n = 20). Participants in the treatment group had all amalgam fillings replaced with other restorative materials. Follow-ups took place 3 months, 1 and 3 years after removal of all amalgam fillings. There was no intervention in the reference group. Subjective health complaints were measured by numeric rating scales in both groups. Analysis of covariance was used to compare changes in health complaints over time in the two groups. In the treatment group, there were significant reductions in intra-oral and general health complaints from inclusion into study to the 3-year follow-up. In the reference group, changes in the same period were not significant. Comparisons between the groups showed that reductions in intra-oral and general health complaints in the treatment group were significantly different from the changes in the reference group. The mechanisms behind this remain to be identified. Reduced exposure to dental amalgam, patient-centred treatment and follow-ups, and elimination of worry are factors that may have influenced the results.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21517933 PMCID: PMC3229679 DOI: 10.1111/j.1365-2842.2011.02223.x
Source DB: PubMed Journal: J Oral Rehabil ISSN: 0305-182X Impact factor: 3.837
Fig. 1Participant flow. Flow diagram showing participant flow in the study. The study is a before-and-after study with a comparison group (reference group). aCurrent addresses were missing for 10 patients; bdid not fulfil inclusion criteria listed in Table 1; cexcluded according to exclusion criteria listed in Table 1; dremoved all amalgam fillings.
Eligibility criteria and number of patients not included. Inclusion criteria were applied based on information from initial examination and Questionnaire 1. Exclusion criteria were applied in the treatment group and reserves, and were applied in relation to the pre-treatment examination in September 2000
| Inclusion criteria | Numbers not fulfilling criterion |
|---|---|
| Referred to the Norwegian Dental Biomaterials Adverse Reaction Unit for examination of health complaints attributed to amalgam fillings | 33 |
| Amalgam fillings still present | 79 |
| No diagnosed contact allergy to substances in resin-based dental materials | 54 |
| Health complaints from at least three different organ systems | 25 |
| Data on mercury in blood and urine from initial examination | 59 |
| Age 25–55 at initial examination | 10 |
| Accepted to be contacted in a follow-up study | 11 |
One hundred and fifty-seven patients did not fulfil one or more of the inclusion criteria.
Completed removal of amalgam fillings since responding to Questionnaire 1.
Fig. 2Timeline for the study. Timeline for the trial for the treatment group and the reference group. Q1, Q2 and Q3 indicate Questionnaire 1, Questionnaire 2 and Questionnaire 3, respectively. Time frames for the activities are indicated for the treatment group (top) and the reference group (bottom).
Descriptive background data. Background data for the treatment group, the reference group and for patients excluded from the treatment group. Data obtained at the initial examination and from Questionnaire 1 (Q1)
| Treatment group ( | Reference group ( | Excluded from treatment group ( | Data from | |
|---|---|---|---|---|
| Women, | 14 (70) | 16 (80) | 8 (80) | |
| Age (years) in September 2000, mean (s.d.) | 46·9 (6·7) | 44·7 (6·5) | 52·6 (7·0) | |
| Education (years), mean (s.d.) | 11·5 (3·6) | 11·3 (2·8) | 10·3 (2·6) | Initial ex. |
| Reported smoking at initial examination, | 4 (20) | 7 (35) | 3 (30) | Initial ex. |
| On sick leave or disability pension, | 9 (45) | 7 (35) | 9 (90) | Q1 |
| Regular dental care, | 17/18 (94) | 20/20 (100) | 6/7 (86) | Q1 |
| Used medication last 12 months, | ||||
| Analgesics | 13 (65) | 13 (65) | 7 (70) | Q1 |
| Antidepressants | 6 (30) | 3 (15) | 2 (20) | |
| Vitamins/dietary supplements | 13 (65) | 13 (65) | 8 (80) | |
| Participants' assessments of risks associated with dental amalgam, | ||||
| Very high | 17 (85) | 15 (75) | 10 (100) | Q1 |
| Medium | 3 (15) | 4 (20) | – | |
| Low | – | – | – | |
| Very low | – | – | – | |
| Missing | – | 1 (5) | – | |
| Number of amalgam surfaces, mean (s.d.) | 36·8 (11·1) | 38·0 (11·3) | 27·2 (16·3) | Initial ex. |
| Concentration of mercury, mean (s.d.) | ||||
| Blood (nmol L−1) | 23·5 (10·4) | 27·5 (12·5) | 33·0 (22·1) | Initial ex. |
| Urine (nmol L−1) | 24·0 (17·6) | 22·0 (16·4) | 21·0 (19·7) | |
| Urine (nmol per mmol creatinine) | 2·7 (1·9) | 2·6 (2·7) | 2·4 (2·3) | |
| Self-reported health complaints, mean (s.d.) | ||||
| Intra-oral index | 8·4 (6·6) | 13·0 (12·0) | 11·2 (7·2) | Q1 |
| Extra-oral index | 6·9 (8·4) | 11·0 (9·3) | 9·2 (8·0) | |
| General index | 41·5 (16·0) | 47·3 (21·2) | 42·3 (15·0) | |
Five patients did not answer the question but had started removal of amalgam restorations.
Comparisons of changes in health complaints in the treatment group and the reference group. Per-protocol (PP) and intention-to-treat (ITT) comparisons of changes in health complaints from Questionnaire 1 to the 3-year follow-up in the treatment group and Questionnaire 3 in the reference group. Mean changes in index scores and mean differences in changes in index scores (mean changes in the treatment group minus mean changes in the reference group) are given
| Difference Questionnaire 1- to 3-year follow-up | Unadjusted differences in changes in index scores | Adjusted difference in changes in index scores | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Mean | 95% CI | Mean | 95% CI | Mean | 95% CI | ||||
| Intra-oral index | |||||||||
| Treatment group (PP) | 19 | 3·7 | 0·5 to 6·9 | ||||||
| Reference group (PP) | 13 | −4·2 | −11·6 to 3·1 | ||||||
| Treatment–reference (PP) | 7·9 | 1·1 to 14·7 | 0·024 | 8·1 | 1·9 to 14·2 | 0·012 | |||
| Treatment group (ITT) | 20 | 3·5 | 0·4 to 6·6 | ||||||
| Reference group (ITT) | 20 | −0·6 | −6·4 to 5·2 | ||||||
| Treatment–reference (ITT) | 4·1 | −2·3 to 10·5 | 0·200 | 6·9 | 1·3 to 12·4 | 0·016 | |||
| Extra-oral index | |||||||||
| Treatment group (PP) | 19 | 1·5 | −2·8 to 5·8 | ||||||
| Reference group (PP) | 13 | −1·8 | −7·9 to 4·3 | ||||||
| Treatment–reference (PP) | 3·2 | −3·7 to 10·2 | 0·346 | 5·5 | −0·4 to 11·4 | 0·066 | |||
| Treatment group (ITT) | 20 | 2·0 | −2·2 to 6·2 | ||||||
| Reference group (ITT) | 20 | −0·6 | −4·8 to 3·6 | ||||||
| Treatment–reference (ITT) | 2·6 | −3·1 to 8·3 | 0·365 | 4·3 | −1·6 to 10·3 | 0·145 | |||
| General index | |||||||||
| Treatment group (PP) | 19 | 9·7 | 4·4 to 15·0 | ||||||
| Reference group (PP) | 13 | −8·7 | −21·4 to 4·0 | ||||||
| Treatment–reference (PP) | 18·4 | 6·8 to 30·0 | 0·003 | 17·4 | 5·8 to 29·0 | 0·005 | |||
| Treatment group (ITT) | 20 | 10·1 | 5·0 to 15·2 | ||||||
| Reference group (ITT) | 20 | −2·3 | −13·1 to 8·5 | ||||||
| Treatment–reference (ITT) | 12·4 | 0·9 to 23·9 | 0·036 | 14·2 | 2·4 to 26·0 | 0·020 | |||
Level of significance: P < 0·05.
For the reference group, data from Questionnaire 3 were used.
Independent-sample t-test comparing changes in index scores in the treatment group and the reference group.
Analysis of covariance of changes in index scores in the treatment group and the reference group, adjusted for gender, age and health complaints from Questionnaire 1.
Positive values indicate reduced health complaints, and negative values indicate increased health complaints.
Repeated measures analysis of changes in health complaints over time. Per-protocol (PP) and intention-to-treat (ITT) repeated measures analysis of changes in health complaints in the treatment group and the reference group. Mean index scores, standard deviations (s.d.) and P-values for within-group changes over time are given
| Questionnaire 1 | Pre-treatment examination | 3-month follow-up | 1-year follow-up | 3-year follow-up | |||
|---|---|---|---|---|---|---|---|
| Mean (s.d.) | Mean (s.d.) | Mean (s.d.) | Mean (s.d.) | Mean (s.d.) | |||
| Treatment group | |||||||
| Intra-oral index (PP) | 18 | 8·6 (6·9) | 6·6 (3·8) | 6·7 (4·5) | 4·7 (5·2) | 5·2 (3·8) | 0·026 |
| Intra-oral index (ITT) | 20 | 8·4 (6·6) | 6·8 (3·7) | 6·4 (4·5) | 4·8 (5·0) | 4·9 (3·8) | 0·015 |
| Extra-oral index (PP) | 18 | 6·7 (8·8) | 6·7 (7·1) | 5·7 (6·4) | 2·4 (3·2) | 4·8 (4·3) | 0·004 |
| Extra-oral index (ITT) | 20 | 6·9 (8·4) | 6·8 (6·8) | 5·6 (6·3) | 2·8 (3·8) | 4·9 (4·4) | 0·009 |
| General index (PP) | 18 | 41·4 (16·4) | 42·9 (21·3) | 39·0 (24·3) | 32·1 (19·2) | 31·6 (14·5) | 0·001 |
| General index (ITT) | 20 | 41·5 (16·0) | 42·7 (20·4) | 37·9 (23·2) | 31·6 (18·5) | 31·4 (13·9) | <0·001 |
| Reference group | |||||||
| Intra-oral index (PP) | 12 | 11·0 (12·0) | n.a. | n.a. | 10·8 (12·8) | 15·4 (13·4) | 0·245 |
| Intra-oral index (ITT) | 20 | 13·0 (12·0) | n.a. | n.a. | 11·3 (12·4) | 13·6 (12·2) | 0·246 |
| Extra-oral index (PP) | 12 | 10·8 (10·6) | n.a. | n.a. | 9·4 (11·4) | 12·5 (12·6) | 0·179 |
| Extra-oral index (ITT) | 20 | 11·0 (9·3) | n.a. | n.a. | 10·0 (10·0) | 11·6 (10·8) | 0·259 |
| General index (PP) | 12 | 43·1 (18·1) | n.a. | n.a. | 38·3 (23·3) | 49·5 (28·5) | 0·004 |
| General index (ITT) | 20 | 47·3 (21·2) | n.a. | n.a. | 41·3 (25·2) | 49·6 (27·3) | 0·004 |
n.a., not applicable.
P-value from analysis of variance for repeated measures.
For the reference group, mean index scores from Questionnaire 2 were used.
For the reference group, mean index scores from Questionnaire 3 were used.
Wilks’ Lambda.
Fig. 3Individual index scores from 3-year follow-up and Questionnaire 3 plotted against scores from Questionnaire 1. Index scores for intra-oral, extra-oral and general health complaints from treatment group (left column) at 3-year follow-up plotted against index scores before amalgam removal (Questionnaire 1). For the reference group (right column), index scores from Questionnaire 3 were plotted against index scores from Questionnaire 1. Data from intention-to-treat analyses (last value carried forward) are marked with grey dots in the diagrams. Results from statistical analyses of data are given in Table 3.
Fig. 4Mean mercury concentration in serum and urine at pre-treatment examination and at follow-up after removal of amalgam fillings. Mean mercury concentration (and s.d.) in serum (nmol L−1) and urine (nmol per mmol creatinine) at pre-treatment examination and at follow-up after removal of amalgam fillings. Mercury concentration in both serum and urine was significantly reduced after amalgam removal (P < 0·001, and P = 0·004, respectively).